(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/053662 A1

(51) International Patent Classification[7]: A61K 31/00, 31/502, A61P 35/00

(21) International Application Number: PCT/GB2004/005025

(22) International Filing Date: 30 November 2004 (30.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/526,244	1 December 2003 (01.12.2003)	US
0327844.7	1 December 2003 (01.12.2003)	GB

(71) Applicants *(for all designated States except US)*: **KUDOS PHARMACEUTICALS LIMITED** [GB/GB]; 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **THE INSTITUTE OF CANCER RESEARCH** [GB/GB]; 123 Old Brompton Road, London Greater London SW7 3RP (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ASHWORTH, Alan** [GB/GB]; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 123 Old Brompton Road, London Greater London SW7 3RP (GB). **JACKSON, Stephen** [GB/GB]; KuDOS Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **MARTIN, Niall** [GB/GB]; KuDOS Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB). **SMITH, Graeme** [GB/GB]; KuDOS Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WG (GB).

(74) Agents: **SUTCLIFFE, Nicholas** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER

(57) Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

WO 2005/053662 A1